ten-bagger

10n

[Proactive @proactive_x]

hVIVO secures Traws influenza challenge study @hVIVO_UK https://t.co/Ma6RavYcH7 #Health #Trial #Clinical #Drug #Development #Traws #HVO

[UK Investor Magazine @UKInvestorMAG]

hVIVO lands influenza challenge trial contract with Traws Pharma https://t.co/mqt1oznFOb

[David Burton ⭐️⭐️ @DavidBurton1971]

🚨 New Contract Win for #HVO 🚨

@hVIVO_UK signs Influenza Human Challenge Trial with Traws Pharma 🔬

✔️ Phase 2a study (c.150 participants)
✔️ Testing novel antiviral (TXM) for flu + bird flu
✔️ Conducted at Canary Wharf facilities
✔️ Revenue largely recognised in 2026

💡 Big picture:
Human challenge trials = faster, more efficient drug development

With >5,000 participants across past studies, hVIVO continues to position itself as a go-to partner for Big Pharma & biotech

📈 Another contract. Another validation of the model.

https://t.co/o27dCnx2AW

[hVIVO @hVIVO_UK]

Our Chairman, Cathal Friel has been shortlisted for the @NED_Awards in association with @PeelHunt, featured in the @thetimes this past weekend.

Cathal has co-founded & IPO'd five public companies, bringing many years of experience in both Executive and Non-Executive roles with a focus on M&A transactions and strategic growth.

Read full article:
https://t.co/cIkCZUtA53

#HVO #NED #AIM #PublicCompanies #Awards #Shortlisted

[hVIVO @hVIVO_UK]

We have signed a contract with #InhalonBiopharma to assess their inhaled IN-002 #antiviral candidate using our world leading #RSV human challenge model.

🔬 Phase 2a randomised, double-blinded placebo-controlled HCT
🧑@Flucamp to enrol healthy volunteers for study
🏙️ Expected to commence H2 2026 at #CanaryWharf state-of-the-art facility
💰 Revenue expected to be recognised in 2026

Learn more:
https://t.co/mr7rj0xOG9

#HVO #ScientificResearch #HCT #CHIM #ClinicalTrials #FluCamp

[Share_Talk ™ @Share_Talk]

@hVIVO_UK Largest standalone lab contract signed to date #HVO has signed a new £2.7m contract with a US-based biotechnology client bringing the total value of this project to date to £3.2m. hLAB will act as the only contracted virology lab for an international, multi-site Phase 2 field study for the US biotechnology client’s influenza drug candidate.

hLAB will provide virology and immunology lab services across the 5,000 subjects recruited in this trial.

This £2.7m contract brings the total value of this project to £3.2m, the majority of revenue from this new contract is expected to be recognized in 2025 with remainder in 2026.

Prior to the move to our new site in Canary Wharf our labs were at capacity analysing samples from our human challenge trials, following the move to our state-of-the-art facility, we have capacity to sign contracts such as these to support our clients’ preclinical and clinical drug development as a standalone service.

This is is significant step for hVIVO as it highlights delivery on the diversification of our services, supporting our growth strategy. https://t.co/IWjCn332g2 via @Share_Talk

[hVIVO @hVIVO_UK]

Our CEO spoke to Steve Darling at @proactive_UK on this mornings #hLAB contract with a US-based biotechnology client:

🔍 Overview of hLAB
1️⃣Significance of acting as sole virology lab
🔬 Canary Wharf impact & expanded capacity

Watch here:
https://t.co/o3BCZX0K7B

#HVO #hLAB #LabServices #Virology #ScientificStudy #ScientificResearch

[Vox Markets @VOXmarkets]

hVIVO PLC - £3.2m hLAB project #HVO @hVIVO_UK

https://t.co/dXv5R9arSP #voxmarkets #investing #shares via @voxmarkets

[Proactive @proactive_x]

$HVO hVIVO lands largest standalone lab contract to date https://t.co/7QUvr82Vqv @hVIVO_UK #HVO

[ten-bagger @tenbagger8]

Poolbeg Pharma #POLB

HOOKIPA Pharma Inc (NASDAQ: HOOK) - Fundraise Presentation:

https://t.co/K4FyAQrJkH

@PoolbegPharma @HookipaPharma $HOOK

[hVIVO @hVIVO_UK]

2024 was an incredible year of achievements for the hVIVO Group🎉. Over the past year we have moved to our new HQ in Canary Wharf, the world's largest commercial human challenge unit, and successfully expanded our service offering.

hVIVO is committed to transforming global healthcare by revolutionising drug development process through scientific innovation and ingenuity.

Check out some of the highlights of the year in our 2024 Year in Review! Here's to even more milestones in 2025! 🥂

#HVO #YearInReview #Goodbye2024

[hVIVO @hVIVO_UK]

Our CEO caught up with @VOXmarkets on a transformational year for hVIVO:

⏪ Recap on 2024
🏙️ World’s largest commercial challenge facility in Canary Wharf
🔬 Expanded services
🚀 2025 & beyond - targetting £100m revenue by 2028

Watch it here:
https://t.co/WlobsmAG5h

#HVO #VOXMarkets #AIM

[hVIVO @hVIVO_UK]

We will be attending the HIC-VAC annual meeting on the 28-29 November in #Liverpool. The theme for this year's conference is "the role of human infection challenge in accelerating #vaccinology".

Reach out to our Brandon Londt on LinkedIn, who will be attending of behalf of #HVO and will be there representing the world leaders in human challenge trials and sharing our deep knowledge on human challenge models, used to aid #scientific research in #infectiousdisease.

We look forward to seeing you there.

#HVO #HICVAC #Conference #ScientificResearch #CHIM

[🇬🇧 𝑻𝒉𝒆 𝑫𝒐𝒄 🇨🇾 @DDS_DocHoliday]

#HVO Octopus increase TR1

https://t.co/5m68jXJtOE

[Steve @Steve03949225]

#HVO 🤔

[hVIVO @hVIVO_UK]

This year our hLAB colleagues will be attending @vaccinenation #WVCEU to showcase their industry leading expertise in #virology, #immunology & molecular laboratory services.

🔬hVIVO Booth: 120
👩‍🔬hLAB Booth: 85

👉Follow #hLAB on LinkedIn for all of their exciting updates

#HVO

[hVIVO @hVIVO_UK]

We were featured as an "exciting" company "that deserves a high valuation" in a @UKInvestorMAG article

🎯 £100m revenue target for 2028
📈 Revenue H1 2024 up 30%
🏙️ New state-of-the-art facility
✅ Record number of volunteers

https://t.co/VZNN5WeM6r

#HVO

[hVIVO @hVIVO_UK]

Our Head of #QA on the new #CanaryWharf state-of-the-art facility benefits the quality assurance & compliance:

💼 Role at #HVO - providing #regulatory support for #HCT's
✅ New facility = maximum efficiency for process flows
🏙️ What excites Teja most about #CanaryWharf

[hVIVO @hVIVO_UK]

Congratulations to @EnantaPharma on the positive topline results in the Phase 2a RSV human challenge trial for their antiviral product, EDP-323. The drug has been shown to be safe and effective using the challenge trial concept. We have already conducted >30 #RSV human challenge trials, we are pleased to add another success story to our portfolio.

Learn more:
https://t.co/hYW0XcJysz

#HVO #RSV #ScientificResearch #HCT #RespiratoryVirus #CHIM